These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12720065)

  • 21. Placebo-controlled trial of sertraline in the treatment of binge eating disorder.
    McElroy SL; Casuto LS; Nelson EB; Lake KA; Soutullo CA; Keck PE; Hudson JI
    Am J Psychiatry; 2000 Jun; 157(6):1004-6. PubMed ID: 10831483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.
    Fichter MM; Krüger R; Rief W; Holland R; Döhne J
    J Clin Psychopharmacol; 1996 Feb; 16(1):9-18. PubMed ID: 8834413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial.
    Leombruni P; Lavagnino L; Gastaldi F; Vasile A; Fassino S
    Hum Psychopharmacol; 2009 Aug; 24(6):483-8. PubMed ID: 19536908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic treatment of binge eating disorder.
    Carter WP; Hudson JI; Lalonde JK; Pindyck L; McElroy SL; Pope HG
    Int J Eat Disord; 2003; 34 Suppl():S74-88. PubMed ID: 12900988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.
    McElroy SL; Arnold LM; Shapira NA; Keck PE; Rosenthal NR; Karim MR; Kamin M; Hudson JI
    Am J Psychiatry; 2003 Feb; 160(2):255-61. PubMed ID: 12562571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
    McDougle CJ; Naylor ST; Cohen DJ; Volkmar FR; Heninger GR; Price LH
    Arch Gen Psychiatry; 1996 Nov; 53(11):1001-8. PubMed ID: 8911223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy.
    Schmidt U; Cooper PJ; Essers H; Freeman CP; Holland RL; Palmer RL; Shur E; Russell GF; Bowler C; Coker S; Geddes JR; Mackenzie F; Munro J; Newton R; Tiller J; Tattersall ML; Vize C; Webster J
    J Clin Psychopharmacol; 2004 Oct; 24(5):549-52. PubMed ID: 15349014
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder.
    Escalona R; Canive JM; Calais LA; Davidson JR
    Depress Anxiety; 2002; 15(1):29-33. PubMed ID: 11816050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial.
    Guerdjikova AI; McElroy SL; Kotwal R; Welge JA; Nelson E; Lake K; Alessio DD; Keck PE; Hudson JI
    Hum Psychopharmacol; 2008 Jan; 23(1):1-11. PubMed ID: 18058852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hollander E; Kaplan A; Schmeidler J; Yang H; Li D; Koran LM; Barbato LM
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):472-7. PubMed ID: 16387985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa.
    Fichter MM; Leibl C; Krüger R; Rief W
    Pharmacopsychiatry; 1997 May; 30(3):85-92. PubMed ID: 9211569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
    Farahani RH; Ajam A; Naeini AR
    BMC Infect Dis; 2023 Mar; 23(1):197. PubMed ID: 37003990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of sertraline for bulimia nervosa.
    Sloan DM; Mizes JS; Helbok C; Muck R
    Int J Eat Disord; 2004 Jul; 36(1):48-54. PubMed ID: 15185271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.